Caveola-forming proteins caveolin-1 and PTRF in prostate cancer

Nature Reviews Urology

Volumn 10, Issue 9, 2013, Pages 529-536

  Nassar, Zeyad D ^a   Hill, Michelle M ^a   Parton, Robert G ^a   Parat, Marie Odile ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; COLLAGEN; GELATINASE B; POLYMERASE I AND TRANSCRIPT RELEASE FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CAVEOLA; CELL MEMBRANE; DNA METHYLATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HORMONE ACTION; HUMAN; METASTASIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REVIEW; STROMA CELL; TUMOR SUPPRESSOR GENE;

CAVEOLAE; CAVEOLIN 1; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA-BINDING PROTEINS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883740020     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.168     Document Type: Review

References (126)

1. Parton, R. G. & del Pozo, M. A. Caveolae as plasma membrane sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 14, 98-112 (2013).
2. Parton, R. G. & Simons, K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8, 185-194 (2007).
3. Gobbo, M. G., Taboga, S. R., Ribeiro, D. L. & Goes, R. M. Short-term stromal alterations in the rat ventral prostate following alloxan-induced diabetes and the influence of insulin replacement. Micron 43, 326-333 (2012).
4. Wong, Y. C. & Tam, N. N. C. Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Differentiation 70, 633-645 (2002).
5. Gallardo-Arrieta, F. et al. Ultrastructural changes in prostate cells during hormone-induced canine prostatic hyperplasia. Ultrastruct. Pathol. 30, 435-442 (2006).
6. Gould, M. L., Williams, G. & Nicholson, H. D. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 70, 1609-1621 (2010).
7. Razani, B. et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121-38138 (2001).
8. Zhao, Y. Y. et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl Acad. Sci. USA 99, 11375-11380 (2002).
9. Drab, M. et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452 (2001).
10. Schubert, W. et al. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice. J. Biol. Chem. 277, 40091-40098 (2002).
11. Park, D. S. et al. Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry 42, 15124-15131 (2003).
12. Cohen, A. W. et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 284, C457-C474 (2003).
13. Wunderlich, C. et al. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem. Biophys. Res. Commun. 340, 702-708 (2006).
14. Albinsson, S. et al. Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1222-R1231 (2007).
15. Hassan, G. S., Jasmin, J. F., Schubert, W., Frank, P. G. & Lisanti, M. P. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 43, 8312-8321 (2004).
16. Rosengren, B. I. et al. Transvascular protein transport in mice lacking endothelial caveolae. Am. J. Physiol. Heart Circ. Physiol. 291, H1371-H1377 (2006).
17. Yu, J. et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J. Clin. Invest. 116, 1284-1291 (2006).
18. Razani, B. et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 277, 8635-8647 (2002).
19. Cohen, A. W. et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am. J. Physiol. Cell Physiol. 285, C222-C235 (2003).
20. Fernandez, M. A. et al. Caveolin-1 is essential for liver regeneration. Science 313, 1628-1632 (2006).
21. Frank, P. G., Pavlides, S., Cheung, M. W., Daumer, K. & Lisanti, M. P. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am. J. Physiol. Cell Physiol. 295, C242-C248 (2008).
22. Liu, L. et al. Deletion of cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 8, 310-317 (2008).
23. Cao, G. et al. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am. J. Pathol. 162, 1241-1248 (2003).
24. Woodman, S. E. et al. Urogenital alterations in aged male caveolin-1 knockout mice. J. Urol. 171, 950-957 (2004).
25. Le Lay, S. & Kurzchalia, T. V. Getting rid of caveolins: Phenotypes of caveolin-deficient animals. Biochim. Biophys. Acta 1746, 322-333 (2005).
26. Sadegh, M. K. et al. Biomechanical properties and innervation of the female caveolin-1-deficient detrusor. Br. J. Pharmacol. 162, 1156-1170 (2011).
27. Karbalaei, M. S. et al. Impaired contractility and detrusor hypertrophy in cavin-1-deficient mice. Eur. J. Pharmacol. 689, 179-185 (2012).
28. Thompson, T. C. et al. The role of caveolin-1 in prostate cancer: Clinical implications. Prostate Cancer Prostatic Dis. 13, 6-11 (2010).
29. Hill, M. M. et al. PTRF-cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 132, 113-124 (2008).
30. Inder, K. L. et al. Expression of PTRF in PC-3 cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways. Mol. Cell. Proteomics 11, M111.012245 (2011).
31. Aung, C. S., Hill, M. M., Bastiani, M., Parton, R. G. & Parat, M. O. PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: Role of matrix metalloprotease 9. Eur. J. Cell Biol. 90, 136-142 (2010).
32. Hill, M. M. et al. Co-regulation of cell polarization and migration by caveolar proteins PTRF/Cavin-1 and caveolin-1. PLoS ONE 7, e43041 (2012).
33. Pelkmans, L. & Zerial, M. Kinase-regulated quantal assemblies and kiss-and-run recycling of caveolae. Nature 436, 128-133 (2005).
34. Galbiati, F. et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J. Biol. Chem. 276, 21425-21433 (2001).
35. Razani, B. et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol. Cell. Biol. 22, 2329-2344 (2002).
36. Couet, J., Li, S., Okamoto, T., Ikezu, T. & Lisanti, M. P. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272, 6525-6533 (1997).
37. Okamoto, T., Schlegel, A., Scherer, P. E. & Lisanti, M. P. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273, 5419-5422 (1998).
38. Byrne, D. P., Dart, C. & Rigden, D. J. Evaluating caveolin interactions: Do proteins interact with the caveolin scaffolding domain through a widespread aromatic residue-rich motif? PLoS ONE 7, e44879 (2012).
39. Collins, B., Davis, M., Hancock, J. & Parton, R. Structure-based reassessment of the caveolin signaling model: Do caveolae regulate signaling through caveolin-protein interactions? Dev. Cell 23, 11-20 (2012).
40. Glenney, J. R. Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J. Biol. Chem. 264, 20163-20166 (1989).
41. Galbiati, F. et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol. Biol. Cell 12, 2229-2244 (2001).
42. Engelman, J. A. et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 272, 16374-16381 (1997).
43. Capozza, F. et al. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am. J. Pathol. 162, 2029-2039 (2003).
44. Williams, T. M. et al. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol. Biol. Cell 14, 1027-1042 (2003).
45. Williams, T. M. et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279, 51630-51646 (2004).
46. Engelman, J. A., Zhang, X. L. & Lisanti, M. P. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 436, 403-410 (1998).
47. van Golen, K. L. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis? Expert Opin. Ther. Targets 10, 709-721 (2006).
48. Goetz, J., Lajoie, P., Wiseman, S. & Nabi, I. Caveolin-1 in tumor progression: The good, the bad and the ugly. Cancer Metastasis Rev. 27, 715-735 (2008).
49. Ando, T. et al. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol. Rep. 18, 601-609 (2007).
50. Wikman, H. et al. Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays. J. Pathol. 203, 584-593 (2004).
51. Fong, A. et al. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 120, 93-100 (2003).
52. Savage, K. et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 13, 90-101 (2007).
53. Eynden, G. et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res. Treat. 95, 219-228 (2006).
54. Elsheikh, S. E. et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer 99, 327-334 (2008).
55. Sagara, Y. et al. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br. J. Cancer 91, 959-965 (2004).
56. Yang, G. et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4, 1873-1880 (1998).
57. Tahir, S. A. et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61, 3882-3885 (2001).
58. Satoh, T. et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97, 1225-1233 (2003).
59. Yang, G., Timme, T. L., Frolov, A., Wheeler, T. M. & Thompson, T. C. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103, 1186-1194 (2005).
60. Gumulec, J. et al. Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol. Rep. 27, 831-841 (2012).
61. Karam, J. A. et al. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67, 614-622 (2007).
62. Yang, G. et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum. Pathol. 38, 1688-1695 (2007).
63. Yang, G., Truong, L. D., Wheeler, T. M. & Thompson, T. C. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res. 59, 5719-5723 (1999).
64. Tahir, S. A. et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin. Cancer Res. 12, 4872-4875 (2006).
65. Bachmann, N. et al. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet. Cytogenet. 182, 103-110 (2008).
66. Steiner, I., Jung, K., Miller, K., Stephan, C. & Erbersdobler, A. Expression of endothelial factors in prostate cancer: A possible role of caveolin-1 for tumour progression. Oncol. Rep. 27, 389-395 (2012).
67. Wu, H. C. et al. Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res. 31, 745-749 (2011).
68. Haeusler, J. et al. Association of a CAV-1 haplotype to familial aggressive prostate cancer. Prostate 65, 171-177 (2005).
69. Cui, J. et al. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46, 249-256 (2001).
70. Langeberg, W. J. et al. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70, 1020-1035 (2010).
71. Li, L. et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61, 4386-4392 (2001).
72. Timme, T. L. et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19, 3256-3265 (2000).
73. Li, L. et al. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol. Cancer Res. 7, 1781-1791 (2009).
74. Tahir, S. A., Park, S. & Thompson, T. C. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol. Ther. 8, 2286-2296 (2009).
75. Nasu, Y. et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat. Med. 4, 1062-1064 (1998).
76. Williams, T. M. et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J. Biol. Chem. 280, 25134-25145 (2005).
77. Watanabe, M. et al. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol. Cancer Res. 7, 1446-1455 (2009).
78. Tahir, S. A. et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 68, 731-739 (2008).
79. Liu, P., Li, W. P., Machleidt, T. & Anderson, R. G. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat. Cell Biol. 1, 369-375 (1999).
80. Li, W. P., Liu, P., Pilcher, B. K. & Anderson, R. G. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J. Cell Sci. 114, 1397-1408 (2001).
81. Thomas, D. D. H., Krzykowski, K. J., Engelke, J. A. & Groblewski, G. E. Exocrine pancreatic secretion of phospholipid, menaquinone-4, and caveolin-1 in vivo. Biochem. Biophys. Res. Commun. 319, 974-979 (2004).
82. Bartz, R. et al. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int. J. Cancer 122, 520-525 (2008).
83. Burden, H. P., Holmes, C. H., Persad, R. & Whittington, K. Prostasomes - their effects on human male reproduction and fertility. Hum. Reprod. Update 12, 283-292 (2006).
84. Llorente, A., de Marco, M. C. & Alonso, M. A. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J. Cell Sci. 117, 5343-5351 (2004).
85. Tavoosidana, G. et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl Acad. Sci. USA 108, 8809-8814 (2011).
86. Ronquist, K. G., Ronquist, G., Larsson, A. & Carlsson, L. Proteomic analysis of prostate cancer metastasis-derived prostasomes. Anticancer Res. 30, 285-290 (2010).
87. Di Vizio, D. et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am. J. Pathol. 181, 1573-1584 (2012).
88. Ayala, G. E. et al. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 66, 5159-5164 (2006).
89. Kuo, S. R. et al. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma (Larchmt) 31, 77-86 (2012).
90. Di, V. D. et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 8, 2420-2424 (2009).
91. Giatromanolaki, A., Koukourakis, M. I., Koutsopoulos, A., Mendrinos, S. & Sivridis, E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol. Ther. 13, 1284-1289 (2012).
92. Moon, H. PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene (in press).
93. Yang, G. et al. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol. Cancer Res. 10, 218-229 (2012).
94. Tahir, S. A. et al. Development of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancer. Clin. Cancer Res. 9, 3653-3659 (2003).
95. Tahir, S. A. et al. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models. Cancer Biol. Ther. 14, 117-126 (2013).
96. Bastiani, M. et al. MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes. J. Cell Biol. 185, 1259-1273 (2009).
97. Liu, L. & Pilch, P. F. A critical role of cavin (PTRF) in caveolae formation and organization. J. Biol. Chem. 283, 4314-4322 (2008).
98. Hansen, C. G., Bright, N. A., Howard, G. & Nichols, B. J. SDPR induces membrane curvature and functions in the formation of caveolae. Nat. Cell. Biol. 11, 807-814 (2009).
99. McMahon, K. A. et al. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J. 28, 1001-1015 (2009).
100. Bastiani, M. & Parton, R. G. Caveolae at a glance. J. Cell Sci. 123, 3831-3836 (2010).
101. Jansa, P. & Grummt, I. Mechanism of transcription termination: PTRF interacts with the largest subunit of RNA polymerase I and dissociates paused transcription complexes from yeast and mouse. Mol. Gen. Genet. 262, 508-514 (1999).
102. Jansa, P., Mason, S. W., Hoffmann-Rohrer, U. & Grummt, I. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes. EMBO J. 17, 2855-2864 (1998).
103. Jansa, P., Burek, C., Sander, E E. & Grummt, I. The transcript release factor PTRF augments ribosomal gene transcription by facilitating reinitiation of RNA polymerase I. Nucleic Acids Res. 29, 423-429 (2001).
104. Vinten, J., Johnsen, A. H., Roepstorff, P., Harpoth, J. & Tranum-Jensen, J. Identification of a major protein on the cytosolic face of caveolae. Biochim. Biophys. Acta 1717, 34-40 (2005).
105. Volonte, D. & Galbiati, F. Polymerase I and transcript release factor (PTRF)/cavin-1 is a novel regulator of stress-induced premature senescence. J. Biol. Chem. 286, 28657-28661 (2011).
106. Bai, L. et al. Regulation of cellular senescence by the essential caveolar component PTRF/Cavin-1. Cell Res. 21, 1088-1101 (2011).
107. Zhu, H. et al. Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J. Biol. Chem. 286, 12820-12824 (2011).
108. Aboulaich, N., Chui, P. C., Asara, J. M., Flier, J. S. & Maratos-Flier, E. Polymerase I and transcript release factor regulates lipolysis via a phosphorylation-dependent mechanism. Diabetes 60, 757-765 (2011).
109. Kozak, L. P., Newman, S., Chao, P. M., Mendoza, T. & Koza, R. A. The early nutritional environment of mice determines the capacity for adipose tissue expansion by modulating genes of caveolae structure. PLoS ONE 5, e11015 (2010).
110. Hayashi, Y. K. et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J. Clin. Invest. 119, 2623-2633 (2009).
111. Rajab, A. et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 6, e1000874 (2010).
112. Dwianingsih, E. K. et al. A Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy type 4. Mol. Genet. Metab. 101, 233-237 (2010).
113. Shastry, S. et al. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am. J. Med. Genet. 152A, 2245-2253 (2010).
114. Thommen, D. S. et al. Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL. J. Immunol. 188, 5283-5292 (2012).
115. Guha, U. et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc. Natl Acad. Sci. USA 105, 14112-14117 (2008).
116. Bai, L. et al. Down-regulation of the cavin family proteins in breast cancer. J. Cell. Biochem. 113, 322-328 (2012).
117. Gamez-Pozo, A. et al. PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. PLoS ONE 7, e33752 (2012).
118. Shen, J. et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western array and immunohistochemistry. Cancer Res. 66, 11194-11206 (2006).
119. Yi, J. S. et al. PTRF/Cavin-1 is essential for multidrug resistance in cancer cells. J. Proteome Res. 12, 605-614 (2012).
120. Allen, W. L. et al. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol. Cancer Ther. 11, 119-131 (2012).
121. Joshi, B. et al. Phosphocaveolin-1 is a mechanotransducer that induces caveola biogenesis via Egr1 transcriptional regulation. J. Cell Biol. 199, 425-435 (2012).
122. Eid, M. A., Kumar, M. V., Iczkowski, K. A., Bostwick, D. G. & Tindall, D. J. Expression of early growth response genes in human prostate cancer. Cancer Res. 58, 2461-2468 (1998).
123. Hasegawa, T. et al. PTRF (polymerase I and transcript-release factor) is tissue-specific and interacts with the BFCOL1 (binding factor of a type-I collagen promoter) zinc-finger transcription factor which binds to the two mouse type-I collagen gene promoters. Biochem. J. 347, 55-59 (2000).
124. Ortegren, U., Aboulaich, N., Ost, A. & Stralfors, P. A new role for caveolae as metabolic platforms. Trends Endocrinol. Metab. 18, 344-349 (2007).
125. Fu, Y. et al. Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J. Biol. Chem. 279, 14140-14146 (2004).
126. Lee, B. H. et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res. 73, 1211-1218 (2012).